Can an SGLT‑2 inhibitor be initiated in an adult with type 2 diabetes and an estimated glomerular filtration rate of 31 mL/min/1.73 m²?

Yes, SGLT2 Inhibitors Can Be Started at eGFR 31 mL/min/1.73 m²

SGLT2 inhibitors should be initiated in adults with type 2 diabetes and an eGFR of 31 mL/min/1.73 m² based on current guideline recommendations that support initiation down to eGFR ≥20 mL/min/1.73 m² 1.

Guideline-Based Threshold for Initiation

The most recent consensus guidelines from ADA/KDIGO (2022) explicitly recommend:

• SGLT2 inhibitors can be initiated when eGFR ≥20 mL/min/1.73 m² 1
• This represents a significant evolution from earlier thresholds (previously ≥30, then ≥25 mL/min/1.73 m²)
• The 2024 BMJ guideline reinforces that SGLT2 inhibitors should generally not be newly initiated below eGFR <20 mL/min/1.73 m², but your patient at 31 mL/min/1.73 m² is well above this cutoff 2

Evidence Supporting Initiation at This eGFR

The recommendation to initiate at eGFR 31 mL/min/1.73 m² is supported by:

Kidney and cardiovascular protection remains robust at this level of kidney function:

• A 2025 meta-analysis of 70,361 participants demonstrated SGLT2 inhibitors reduce CKD progression consistently across all eGFR categories, including eGFR <30 mL/min/1.73 m² (HR 0.71,95% CI 0.60-0.83) 3
• Benefits occur regardless of albuminuria level - protection is seen even with minimal albuminuria 3
• The CREDENCE and DAPA-CKD trials specifically demonstrated efficacy and safety in patients with eGFR ≥25 mL/min/1.73 m² 1

The benefits extend beyond glucose control:

• At eGFR 31 mL/min/1.73 m², glucose-lowering efficacy is reduced, but kidney and cardiovascular protection are preserved 1
• SGLT2 inhibitors reduce risk of dialysis, transplantation, or death due to kidney disease by 33% (RR 0.67) 4
• They also reduce acute kidney injury risk by 25% (RR 0.75) 4

Specific Drug Considerations at eGFR 30-44 mL/min/1.73 m²

Based on FDA labeling and guideline recommendations 1:

Dapagliflozin:

• Approved at 10 mg daily for eGFR 25 to <45 mL/min/1.73 m²
• Can be initiated at this eGFR level

Canagliflozin:

• Maximum dose 100 mg daily at eGFR 30-44 mL/min/1.73 m²
• Can be initiated at this eGFR level

Empagliflozin:

• 10 mg daily at eGFR 30-44 mL/min/1.73 m²
• FDA labeling states "use not recommended with eGFR <45 mL/min/1.73 m²" for glycemic control, but can be initiated at eGFR ≥20 mL/min/1.73 m² for heart failure indication

Risk Stratification Context

At eGFR 31 mL/min/1.73 m², your patient falls into either:

• High risk (if albuminuria <3 mg/mmol)
• Very high risk (if albuminuria ≥3 mg/mmol)

Both categories warrant SGLT2 inhibitor therapy according to KDIGO risk stratification 2.

Safety Monitoring at This eGFR

Key monitoring points when initiating at eGFR 31 mL/min/1.73 m²:

• Volume status: Monitor for hypovolemia; consider proactive diuretic dose reduction in high-risk patients 1
• Hypoglycemia risk: Adjust insulin or sulfonylurea doses if used concomitantly 1
• Ketoacidosis prevention: Maintain at least low-dose insulin in insulin-requiring patients; implement sick-day protocols (hold SGLT2i during acute illness) 1
• Genital infections: Counsel on hygiene measures 1
• eGFR monitoring: Once initiated, SGLT2 inhibitors can be continued even if eGFR falls below 20 mL/min/1.73 m² until dialysis 2, 5

Common Pitfalls to Avoid

Do not withhold SGLT2 inhibitors due to:

• Reduced glucose-lowering efficacy at lower eGFR - the primary benefit at this stage is cardiorenal protection, not glycemic control 1
• Concern about initiating at eGFR 31 mL/min/1.73 m² - this is well within guideline-supported range
• Absence of albuminuria - benefits are consistent regardless of baseline albuminuria 3

Critical point: The evidence shows that continuation of SGLT2 inhibitors when eGFR deteriorates below 20 mL/min/1.73 m² maintains benefit without additional safety concerns 5, so initiating at 31 mL/min/1.73 m² provides a longer window of protection.